ArticleScience advances2021
Leveraging systems biology for predicting modulators of inflammation in patients with COVID-19.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro.Inflammopharmacology · 2024Review
- Article
- Toll-like receptors in health and disease.MedComm · 2024Review
- SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination.Antibodies (Basel, Switzerland) · 2024Review
- Reductionist methodology and the ambiguity of the categories of race and ethnicity in biomedical research: an exploratory study of recent evidence.Medicine, health care, and philosophy · 2023Article
- Innate immune recognition against SARS-CoV-2.Inflammation and regeneration · 2023Review
- Role of the extracellular matrix in COVID-19.World journal of clinical cases · 2023Review
- Classification and severity progression measure of COVID-19 patients using pairs of multi-omic factors.Journal of applied statistics · 2023Article
- Proteoglycans: a common portal for SARS-CoV-2 and extracellular vesicle uptake.American journal of physiology. Cell physiology · 2023Review
- Innate immunity, cytokine storm, and inflammatory cell death in COVID-19.Journal of translational medicine · 2022Review
- Innate immunity: the first line of defense against SARS-CoV-2.Nature immunology · 2022Review
- Viral infectious diseases severity: co-presence of transcriptionally active microbes (TAMs) can play an integral role for disease severity.Frontiers in immunology · 2022Review
- Fostering experimental and computational synergy to modulate hyperinflammation.Trends in immunology · 2022Article
- ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review.International journal of molecular sciences · 2021Review
- Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19.iScience · 2021Article
- Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer.Frontiers in oncology · 2021Review
- Targeting the Host Response: Can We Manipulate Extracellular Matrix Metalloproteinase Activity to Improve Influenza Virus Infection Outcomes?Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulations in the inflammatory response of the body to pathogens could progress toward a hyperinflammatory condition amplified by positive feedback loops and associated with increased severity and mortality. Hence, there is a need for identifying therapeutic targets to modulate this pathological immune response. Here, we propose a single cell-based computational methodology for predicting proteins to modulate the dysregulated inflammatory response based on the reconstruction and analysis of functional cell-cell communication networks of physiological and pathological conditions. We validated the proposed method in 12 human disease datasets and performed an in-depth study of patients with mild and severe symptomatology of the coronavirus disease 2019 for predicting novel therapeutic targets. As a result, we identified the extracellular matrix protein versican and Toll-like receptor 2 as potential targets for modulating the inflammatory response. In summary, the proposed method can be of great utility in systematically identifying therapeutic targets for modulating pathological immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.